<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31876">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02026518</url>
  </required_header>
  <id_info>
    <org_study_id>459</org_study_id>
    <nct_id>NCT02026518</nct_id>
  </id_info>
  <brief_title>Effect of Cholecalciferol, Soy Isoflavones in Patients With Irritable Bowel Syndrome</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti Medical University</source>
  <oversight_info>
    <authority>Iran: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fasting blood specimens will be taken from the patients with IBS that have inclusion
      criteria. First, the objectives and method of study will be explained to the patients and
      informed consent form will be taken from them. They will be divided into 4 groups by an
      adjusted randomized blocking and the clinical outcomes, quality of life, emotional stress
      questionnaires will be completed before and after intervention. During 6 weeks, they will
      receive 2 capsules of soy isoflavones per day, 50000IU vitamin D biweekly in addition to the
      other placebo form, both of them and placebo of both. At the end, body mass index ( BMI),
      serum TNF-Alpha, TAC, gene expression of GATA3, ROR gamma, FOXP3 in lymphocytes and gut
      permeability will be measured. The quantity of polymorphisms of vitamin D and estrogen
      receptors will be determined.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in Clinical Outcomes (pain, flatulence, diarrhea, constipation ) at 6 weeks</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of baseline in gut permeability as efficacy at 6 weeks</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of baseline in antioxidant status as efficacy at 6 weeks</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of baseline in inflammation status as efficacy at 6 weeks</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Irritable Bowel Disease</condition>
  <arm_group>
    <arm_group_label>Soy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group Soy receiving placebo similar to 50000 IU cholecalciferol (includes MCT oil) biweekly for 6 weeks in addition to 40 milligram (2 capsules per day) soy isoflavones capsules  for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Soy- Cholecalciferol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group Soy- Cholecalciferol receiving Supplement in form of 40 milligrams soy isoflavones (diadzein, genistein, glycitin) per day (2 capsules of 20 milligrams) for 6 weeks in addition to supplement of cholecalciferol (vitamin D3) biweekly for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group Placebo receiving Placebo in similar form of cholecalciferol supplement biweekly for 6 weeks in addition to 40 milligrams placebo in similar form of soy isoflavones including starch for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cholecalciferol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group Cholecalciferol receiving oral Placebo in similar form to soy isoflavones (diadzein, genistein, glycitin) supplement including starch (2 capsules per day) for 6 weeks in addition to 50000 IU cholecalciferol supplement biweekly for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Soy isoflavones</intervention_name>
    <arm_group_label>Soy</arm_group_label>
    <arm_group_label>Soy- Cholecalciferol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>cholecalciferol</intervention_name>
    <arm_group_label>Soy- Cholecalciferol</arm_group_label>
    <arm_group_label>Cholecalciferol</arm_group_label>
    <other_name>Vitamin D</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo of soy isoflavones</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Cholecalciferol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo of cholecalciferol</intervention_name>
    <arm_group_label>Soy</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age 18-75 yrs

          2. patients with Irritable Bowel Syndrome (IBS) according to ROME III criteria

          3. BMI 18-25

          4. a- no intestinal organic diseases b- no intestinal infection c- no history of chronic
             gastrointestinal and colorectal diseases d- no intestinal major surgery

          5. no regular use of antibiotics, anti-constipation and anti-diarrhea, immune
             suppressors, metoclopramide, cisapride, diphenoxylate, opium and non-steroidal
             anti-inflammatory drugs

          6. no pregnancy and lactation

          7. not athlete or bed rest

          8. no history of breast cancer in herself or her family

          9. no severe psychosis

        Exclusion Criteria:

          1. a- use of soy isoflavones or vitamin D one year before the study b- use of soy milk
             or soy nuts during study

          2. diet changes during study

          3. use of artificial sweetener 2 days before study

          4. no desire to complete the study

          5. adverse effect of supplement

          6. pregnancy during study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mahsa Jalili, PhD student</last_name>
    <phone>00989396708282</phone>
    <email>jalili.mah@sbmu.ac.ir</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gastrointestinal Clinics of Tehran University of Medical Sciences</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 31, 2013</lastchanged_date>
  <firstreceived_date>December 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Beheshti Medical University</investigator_affiliation>
    <investigator_full_name>Mahsa Jalili</investigator_full_name>
    <investigator_title>Mrs</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
